• Eradication efficacy helicobacter pylori the combined use of antibacterial and probiotic therapy in children with chronic gastroduodenitis. 
To content

Eradication efficacy helicobacter pylori the combined use of antibacterial and probiotic therapy in children with chronic gastroduodenitis. 

SOVREMENNAYA PEDIATRIYA.2014.2(58):90-94; doi 10.15574/SP.2014.58.90 
 

Eradication efficacy helicobacter pylori the combined use of antibacterial and probiotic therapy in children with chronic gastroduodenitis. 
 

Abaturov A. E., Gerasymenko O. N.

State Establishment «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine» Purpose. 

To study the efficacy of a probiotic containing Lactobacillus rhamnosus strain Rosell-11 (95%) and Lactobacillus acidophilus strain Rosell-52 (5%) in the treatment of H. pylori infection in children.

 

Patients and methods. For treatment of H.pylori-associative chronic gastroduodenitis in 25 children (mean age 13,49±0,54) in the seven-day scheme «triple» of H. pylori eradication therapy used probiotic drugs. Comparison group consisted of children (20), which received only basic «triple» H. pylori therapy. 
 

Results. Shown that during treatment with combination therapy using probiotic preparation is more rapid regression of the intensity of the main disease syndromes, significant increase of sCD14, which is associated with decreased activity of tendentious NF-κB, efficiency eradication H.pylori. 
 

Conclusions. The purpose of the probiotic preparation «Lacidofil» in combination with standard therapy significantly increases the effectiveness of eradication of H.pylori. One of the possible mechanisms of action of probiotic Lactobacillus, contributing to the healing process, we can assume the induction of synthesis of sCD14, which prevents the disruption of the interaction of LPS with H.pylori Toll- like receptors. 
 

Key words: H.pylori, chronic gastroduodenitis, Lacidofil, NF-κB, sCD14, children. 
 

REFERENCES

1. Лацидофил. Institut Rosell. 2009: 43.

2. Johnson C, Dicksved J, Jonsson H, Roos S. 2003. Anti Helicobacter pylori activity among lactic acid bacteria isolated from gastric biopsies and strains of Lactobacillus euteri (abstract). Helicobacter. 8: 473.

3. Midolo PD, Lambert JR, Hull R et al. 1995. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 79(4): 475—9.

4. Lorca GL, Wadstrom T, Valdez GF, Ljungh A. 2001. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 42(1): 39—44. http://dx.doi.org/10.1007/s002840010175

5. Dore MP, Cuccu M, Pes GM et al. 2013, Nov 1. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern Emerg Med.

6. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. 2007. Helicobacter pylori and probiotics. J Nutr. 137;3 Suppl 2: 812—8.

7. Takahashi T, Matsumoto T, Nakamura M et al. 2007. L-lactic acid secreted from gastric mucosal cells enhances growth of Helicobacter pylori. Helicobacter. 12(5): 532—40. doi: 10.1111/j.1523 — 5378.2007.00524.x.

8. Li S, Huang XL, Sui JZ et al. 2013, Dec 10. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr.

9. Sherman PM, Johnson-Henry KC, Yeung HP et al. 2005. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 73;8: 5183—5188. http://dx.doi.org/10.1128/IAI.73.8.5183-5188.2005; PMid:16041036 PMCid:PMC1201237

10. Zheng X, Lyu L, Mei Z. 2013. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: Evidence from a meta-analysis. Rev Esp Enferm Dig. 105(8): 445—453. http://dx.doi.org/10.4321/S1130-01082013000800002; PMid:24274441